New research finds biological processes that improve prediction of therapeutic performance and provide a framework to develop predictors for this aggressive skin cancer. PHILADELPHIA — (SEPTEMBER 1…
PHILADELPHIA—(September 8, 2022)—The Wistar Institute is pleased to announce the appointment of Michele A. Schiavoni, M.S., as Vice President of Communications & Marketing, in a central leaders…
PHILADELPHIA — (Sept. 7, 2022) — Researchers in the laboratory of Yulia Nefedova, M.D., Ph.D., at The Wistar Institute and collaborators at Jubilant Therapeutics Inc. have uncovered a novel mechani…
PHILADELPHIA — (August 2, 2022) — The National Cancer Institute (NCI) has granted a Merit Extension Award to The Wistar Institute’s Ellen and Ronald Caplan Cancer Center totaling more than $5 milli…
PHILADELPHIA — (July 18, 2022) — Aging and age-related disorders pose a complex challenge to the biomedical research community. To better understand how senescence is regulated is of high significa…
PHILADELPHIA — (July 13, 2022) — The Wistar Institute, an international biomedical research leader in cancer, immunology, and infectious diseases, is pleased to announce the appointment of Gelvina …
PHILADELPHIA — (July 7, 2022) — Under a Defense Advanced Research Projects Agency (DARPA) and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) …
PHILADELPHIA—(June 23, 2022)—The Wistar Institute, a biomedical research leader in cancer, immunology, and infectious disease, announces that for the first time it will globally stream its 26th Ann…
PHILADELPHIA — (June 21, 2022) — Due to the development of resistance to chemotherapy and recurring tumors, patients with ovarian cancer often have low survival rates. Therefore, new therapeutic op…
PHILADELPHIA — (June 16, 2022) —The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious disease, announces its Bold Science // Global Impact Capital C…
